Workflow
美迪西(688202) - 2020 Q1 - 季度财报
MedicilonMedicilon(SH:688202)2020-04-23 16:00

Financial Performance - Operating income for the period was ¥105,877,593.97, representing a year-on-year increase of 20.38%[12] - Net profit attributable to shareholders was ¥15,258,015.35, reflecting a growth of 30.17% compared to the same period last year[12] - The company reported a net profit margin improvement, with retained earnings rising to ¥174.38 million from ¥160.43 million, an increase of 8.67%[39] - Total operating revenue for Q1 2020 reached ¥105,877,593.97, a 20.3% increase from ¥87,951,646.98 in Q1 2019[50] - Net profit for Q1 2020 was ¥15,465,601.25, representing a 32.5% increase compared to ¥11,697,541.44 in Q1 2019[52] - The total profit for Q1 2020 was ¥18,211,426.17, up from ¥13,386,845.32 in Q1 2019[52] - Total comprehensive income for Q1 2020 was ¥13,02 million, compared to ¥11,99 million in Q1 2019, indicating a growth of 8.6%[57] Cash Flow - The net cash flow from operating activities increased by 24.01% to ¥5,077,601.59[12] - The company reported cash inflows from operating activities totaling 79,617,531.27 RMB, compared to 60,569,054.03 RMB in the same period last year, representing a year-over-year increase of approximately 31.4%[62] - Cash flow from operating activities for Q1 2020 was 3,627,233.92 RMB, a significant improvement from -947,980.25 RMB in Q1 2019, indicating a positive cash flow trend[62] - Cash inflow from investment activities was ¥71.65 million, with a net cash flow from investment activities of ¥47.08 million, a significant recovery from a negative cash flow in Q1 2019[60] - The company’s cash flow from financing activities showed a net outflow of 1,900,000.00 RMB, indicating a reduction in financing activities compared to previous periods[64] Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,142,494,649.52, an increase of 1.26% compared to the end of the previous year[12] - Current assets totaled approximately ¥873.87 million, an increase of 9.35% from ¥799.02 million in the previous year[34] - Non-current assets amounted to ¥268.63 million, down from ¥329.30 million, indicating a decrease of 18.38%[37] - Total liabilities were approximately ¥126.44 million, a decrease of 1.01% from ¥127.73 million[39] - Current liabilities decreased to ¥100.36 million from ¥114.07 million, a reduction of 12.06%[39] - The company’s total liabilities decreased to ¥93,555,392.99 from ¥95,447,583.23 year-over-year[48] Shareholder Information - The total number of shareholders at the end of the reporting period was 3,485[22] - The top shareholder, Chen Jinzhan, holds 15.68% of the shares, totaling 9,722,588 shares[22] - Total equity reached ¥1,000,588,211.68, including ¥62,000,000.00 in paid-in capital and ¥755,736,482.19 in capital reserve[70] Research and Development - Research and development expenses accounted for 8.21% of operating income, an increase of 2.46 percentage points from the previous year[15] - Research and development expenses rose by 71.89% to RMB 8,696,529.27, attributed to increased investments in self-developed projects[28] - R&D expenses in Q1 2020 amounted to ¥8,696,529.27, a significant increase of 72.1% from ¥5,059,238.06 in Q1 2019[50] Government Subsidies and Deferred Income - The company received government subsidies amounting to ¥493,582.91 during the reporting period[15] - The deferred income increased significantly to ¥26.08 million from ¥13.66 million, marking a growth of 91.00%[39] - The deferred income increased significantly to ¥21,887,827.85 in Q1 2020 from ¥10,586,565.89 in Q1 2019[48]